166 related articles for article (PubMed ID: 17663633)
1. An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination.
Verderio P; Dittadi R; Marubini E; Pizzamiglio S; Gion M; De Apollonia L; Paradiso A;
Clin Chem Lab Med; 2007; 45(9):1244-50. PubMed ID: 17663633
[TBL] [Abstract][Full Text] [Related]
2. An Italian program of external quality control for chromogranin A (CgA) assay: state of the art of CgA measurement.
Italian Network for Quality Assessment of Tumor Biomarkers Group
Int J Biol Markers; 2005; 20(4):264-8. PubMed ID: 16398409
[TBL] [Abstract][Full Text] [Related]
3. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
4. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
[TBL] [Abstract][Full Text] [Related]
5. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
[TBL] [Abstract][Full Text] [Related]
6. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
Zitella A; Berruti A; Destefanis P; Mengozzi G; Torta M; Ceruti C; Casetta G; Mosca A; Greco A; Rolle L; Aimo G; Aroasio E; Tizzani A; Dogliotti L; Fontana D;
Clin Chim Acta; 2007 Feb; 377(1-2):103-7. PubMed ID: 17034778
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
[TBL] [Abstract][Full Text] [Related]
8. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an ELISA method for the measurement of chromogranin A and comparison with an immunoradiometric method.
Dittadi R; Bertoli I
Int J Biol Markers; 2013 Apr; 28(1):114-6. PubMed ID: 23015397
[No Abstract] [Full Text] [Related]
10. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CisBio ELISA for Chromogranin A Measurement.
Lim M; Erdman P; Cho S; Mathew A; Fleisher M; Thoren KL
J Appl Lab Med; 2019 Jul; 4(1):11-18. PubMed ID: 31639703
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan.
Giovanella L; Squin N; Ghelfo A; Ceriani L
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):344-7. PubMed ID: 17043632
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of three commercially available ELISA kits for the determination of chromogranin A.
Eeckhout K; Van Cotthem K; Guerti K
J Immunoassay Immunochem; 2021 Mar; 42(2):95-105. PubMed ID: 33043835
[TBL] [Abstract][Full Text] [Related]
14. Internal quality control and external quality management of data in practice.
Methods Mol Biol; 2009; 516():517-41. PubMed ID: 19219595
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum.
Berrigan D; Potischman N; Dodd KW; Nicar M; McQuillan G; Lavigne JA; Barrett JC; Ballard-Barbash R
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1017-22. PubMed ID: 17507631
[TBL] [Abstract][Full Text] [Related]
16. A chromogranin A ELISA absent of an apparent high-dose hook effect observed in other chromogranin A ELISAs.
Erickson JA; Grenache DG
Clin Chim Acta; 2016 Jan; 452():120-3. PubMed ID: 26554519
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a new immunoturbidometric assay of human serum lipoprotein (a) to the ELISA and the IRMA methods.
Sundvall J; Sulonen GB; Hiltunen O; Kiuru J; Pursiainen M; Jauhiainen M
Scand J Clin Lab Invest; 1995 Apr; 55(2):171-80. PubMed ID: 7667610
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
19. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
20. Detection of chromogranin A in the adrenal gland extracts of different animal species by an enzyme-linked immunosorbent assay using Thomsen-Friedenreich antigen-specific Amaranthus caudatus lectin.
Akiyoshi H; Sugii S; Nahid MA; Sone K; Tanaka T; Zheng C; Yijyun L; Aoki M; Takenaka S; Shimada T; Shimizu J; Kiyomiya K; Ohashi F
Vet Immunol Immunopathol; 2011 Dec; 144(3-4):255-8. PubMed ID: 22041600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
